

RESEARCH ARTICLE

Open Access



# Signature-tagged mutagenesis screening revealed a novel smooth-to-rough transition determinant of *Salmonella enterica* serovar Enteritidis

Yang Jiao<sup>1,2</sup>, Rongxian Guo<sup>1,2</sup>, Peipei Tang<sup>1,2</sup>, Xilong Kang<sup>1,2</sup>, Junlei Yin<sup>1,2</sup>, Kaiyue Wu<sup>1,2</sup>, Shizhong Geng<sup>1,2</sup>, Qiuchun Li<sup>1,2</sup>, Jun Sun<sup>2,3</sup>, Xiulong Xu<sup>2</sup>, Xiaohui Zhou<sup>4</sup>, Junji Gan<sup>1,2</sup>, Xinan Jiao<sup>1,2</sup>, Xiufan Liu<sup>1,2\*</sup> and Zhiming Pan<sup>1,2\*</sup>

## Abstract

**Background:** *Salmonella enterica* serovar Enteritidis (*S. Enteritidis*) has emerged as one of the most important food-borne pathogens for humans. Lipopolysaccharide (LPS), as a component of the outer membrane, is responsible for the virulence and smooth-to-rough transition in *S. Enteritidis*. In this study, we screened *S. Enteritidis* signature-tagged transposon mutant library using monoclonal antibody against somatic O<sub>9</sub> antigen (O<sub>9</sub> MAb) and O<sub>9</sub> factor rabbit antiserum to identify novel genes that are involved in smooth-to-rough transition.

**Results:** A total of 480 mutants were screened and one mutant with transposon insertion in *rfbG* gene had smooth-to-rough transition phenotype. In order to verify the role of *rfbG* gene, an *rfbG* insertion or deletion mutant was constructed using λ-Red recombination system. Phenotypic and biological analysis revealed that *rfbG* insertion or deletion mutants were similar to the wild-type strain in growth rate and biochemical properties, but the swimming motility was reduced. SE Slide Agglutination test and ELISA test showed that *rfbG* mutants do not stimulate animals to produce agglutinating antibody. In addition, the half-lethal dose (LD<sub>50</sub>) of the *rfbG* deletion mutant strain was 10<sup>6.6</sup>-fold higher than that of the parent strain in a mouse model when injected intraperitoneally.

**Conclusions:** These data indicate that the *rfbG* gene is involved in smooth-to-rough transition, swimming motility and virulence of *S. Enteritidis*. Furthermore, somatic O-antigen antibody-based approach to screen signature-tagged transposon mutants is feasible to clarify LPS biosynthesis and to find suitable markers in DIVA-vaccine research.

**Keywords:** *rfbG* gene, *S. Enteritidis*, Signature-tagged mutagenesis (STM), Smooth-to-rough transition, O<sub>9</sub> MAb

## Background

*Salmonella enterica* serovar Enteritidis (*S. Enteritidis*, SE) has emerged as one of the most important food-borne pathogens for humans, with poultry meat and eggs being the most common sources of human *S. Enteritidis* food-borne infections [1]. Young chicks showed high mortality rate when infected with *S. Enteritidis*. However, in adult chickens, *S. Enteritidis* usually leads to symptomless carriage, and is able to colonize the tissues of the ovary and oviduct of egg-

laying hens which result in egg contamination [2, 3]. Above all, *S. Enteritidis* constitutes a risk for public health.

In *Salmonella*, the lipopolysaccharide (LPS), as a significant component of the outer membrane, is responsible for virulence, smoothness and for mounting cross reactivity [4]. LPS is composed of three major structures—a core polysaccharide unit; the O-antigen, a polysaccharide consisting of repeating units of sugars that extend from the cell surface; and lipid A, a potent activator of the immune response, which anchors the LPS to the outer membrane [5]. Mutations in genes that are required for the synthesis of the LPS often result in a truncated LPS [4]. Mutant strains harboring incomplete

\* Correspondence: xfliu@yzu.edu.cn; zmpan@yzu.edu.cn

<sup>1</sup>Jiangsu Key Laboratory of Zoonosis, Yangzhou University, 48 East Wenhui Road, Yangzhou, Jiangsu 225009, China

Full list of author information is available at the end of the article



LPS due to its truncation in the polysaccharide structure may have a smooth-to-rough transition [6]. Until now, some LPS deficient mutants (for instance, *rfaJ*, *rfaL* or *rfaC*.) have been used to prevent infection caused by fowl typhoid, *Salmonella* Typhimurium and *Salmonella* Choleraesuis [4, 7, 8]. The purpose of this study was to identify novel factors that are involved in smooth-to-rough transition in *S. Enteritidis*.

Signature-tagged mutagenesis (STM) is a powerful tool to identify genes that are associated with a particular phenotype. The STM technique has been applied in several pathogens to identify conditionally essential genes during infection [9–11]. In previous studies in our laboratory, Geng et al. screened an STM bank of 1800 *S. Gallinarum* biovar Pullorum mutants and identified the genes essential for its survival in chickens. The attenuation of 10 mutants was confirmed by *in vivo* and *in vitro* competitive index (CI) studies. One highly attenuated *spiC* mutant was further characterized as a candidate vaccine [11].

Different serotypes of *Salmonella* have different O antigens. O antigens are used for serotyping of *Salmonella*. O9 antigen is one of the antigens produced on *Salmonella* Enteritidis. *Salmonella* Enteritidis with smooth phenotype have O9 antigen and therefore can be agglutinated by O9 antibody [12, 13]. However,

*Salmonella* Enteritidis without O9 antigen would show rough phenotype. In this study, we used home-made monoclonal antibody against somatic O<sub>9</sub> antigen (O<sub>9</sub> MAb) [14] and commercial O<sub>9</sub> factor rabbit antiserum to screen *S. Enteritidis* signature-tagged transposon mutants to identify novel factors involved in smooth-to-rough transition.

## Methods

### Bacteria, plasmids, primers and grow media

Bacterial strains, plasmids and primers used in this study are listed in the Table 1. Wild-type *Salmonella* Enteritidis strain C50041 was used in this study [15]. SE C50041 $\Delta$ *spiC*, which was constructed by suicide plasmid in previous studies in our laboratory, was used as the recipient strain to make the mutant library in this study [16]. The plasmid pUT mini-Tn5Km2 (Cm) was constructed by inserting Cm<sup>R</sup> gene into pUT mini-Tn5Km2. Bacteria were grown in LB broth (Difco). When needed, this medium was supplemented with 1.5% (w/v) Bacto-agar, ampicillin (Amp, 100  $\mu$ g/ml), kanamycin (Km, 50  $\mu$ g/ml) and chloromycetin (Cm, 40  $\mu$ g/ml).

### Construction of the transposon mutant library

According to the PCR-based STM working scheme, pUT mini-Tn5Km2(Cm) was used for transformation

**Table 1** Bacteria, plasmids and primers used in this study

Material	Description/purpose	Source or reference
Strains		
SE C50041	<i>Salmonella enterica</i> serovar Enteritidis; Wild-type; smooth	Hu et al., 2013 [15]
SE C50041 $\Delta$ <i>spiC</i>	$\Delta$ <i>spiC</i> mutant of SE C50041; Recipient strain; smooth	Zeng et al., 2015 [16]
<i>E. coli</i> $\chi$ 7213-pir	Donor strain	Gift from R. Curtiss III
<i>E. coli</i> DH5 $\alpha$	For cloning	Purchased from Takara company
SE C50041 $\Delta$ <i>spiC</i> - <i>rfaG</i> ::Tn5Km2(Cm)	<i>rfaG</i> transposon mutant of SE C50041 $\Delta$ <i>spiC</i>	This study
SE C50041 $\Delta$ <i>rfaG</i>	$\Delta$ <i>rfaG</i> mutant of SE C50041 by $\lambda$ -Red recombination system	This study
<i>S. Pullorum</i> S06004	Negative control in the motility assay	Geng et al., 2009 [30]
Plasmids		
pUT mini-Tn5Km2(Cm)	For cloning	Constructed and stored in our laboratory
pKD3	Cm cassette template	Datsenko & Wanner, 2000 [17]
pKD46	$\lambda$ -Red recombinase expression	Datsenko & Wanner, 2000 [17]
pCP20	FLP recombinase expression	Datsenko & Wanner, 2000 [17]
Primers		
Y linker	5'- CTGCTCGAATCAAGCTTCT -3'	This study
P6U	5'- GAGCTCGAATTCGGCCTAG -3'	This study
<i>rfaG</i> forward	5'- AGGGCTGTGGGAAAAAGTAAAGCTCCGTGGA AAACCTGGAGTAAGTAGTGTGAGGCTGGAGCTGCTTC -3'	This study
<i>rfaG</i> reverse	5'- CTCACGCAGGTTATTTGCTGTCATTACT TTGATTCCTTAAACTTATTTCCATATGAATATCCTCCTTAG -3'	This study

into *E. coli*  $\chi$ 7213-pir, which required 2,6-diaminopimelic acid (DAP) for growth. The transformants were plated on selective LB agar plates containing Amp, Km, Cm and DAP. Thus the donor strain was generated. Conjugation was performed between the donor strain and the recipient strain SE C50041 $\Delta$ *spiC* strain as described previously [11].

Briefly, 400  $\mu$ l of the donor was mixed with 400  $\mu$ l of the recipient. The mixture was immobilized on a 0.45  $\mu$ m pore-size membrane filter placed on LB agar at 30 °C for 24 h. Transconjugants were recovered in 2 ml phosphate-buffered saline (PBS) and a 100  $\mu$ l aliquot was plated on LB agar containing Km and Cm. All the potential conjugants were analysed for exclusive pUT mini-Tn5Km2(Cm) insertion by confirmation of Amp sensitivity. Each transconjugant was grown in a 96-well plate and stored in LB containing 20% glycerol at -80 °C for further use.

#### Screening rough strains from mutant library

Frozen plates of the SE C50041 $\Delta$ *spiC* transposon mutants were defrosted and subcultured by transferring 20  $\mu$ l from each well to a new 96-well plate containing 180  $\mu$ l of LB (containing Km and Cm). Plates were incubated overnight in a shaking incubator at 50 rpm at 37 °C. Subcultured strains were grown on LB agar containing Km and Cm at 37 °C for 16 h.

The slide agglutination tests were performed using O<sub>9</sub> MAb developed previously in our laboratory and O<sub>9</sub> factor rabbit antiserum (SSI<sup>®</sup>SALMONELLA ANTISERA, Denmark). AS handbook indicated, mutant culture from LB agar medium was mixed homogeneously with 1 drop of PBS and 1 drop of the O<sub>9</sub> MAb or O<sub>9</sub> factor rabbit antiserum on a glass slide. After the slide was tilted gently for approx. 1 min, the results were read.

Of the 480 colonies screened, a rough strain from primary screen was further verified by acriflavine agglutination test.

#### Identification of transposon insertion site

Chromosomal DNA was isolated from transposon mutant and completely digested with *Nla*III that cut on either end of the transposon. Meanwhile, an adapter of a double-stranded cassette was generated as described previously [11]. Approximately 80 ng purified DNA from the digested DNA was ligated to 1  $\mu$ g of the adapter using a DNA ligation kit (Takara, Dalian, China) in 10  $\mu$ l at 16 °C for 12 h. The reaction mixture was diluted with double distilled water to 100  $\mu$ l as templates in the PCR amplification. Sequencing of DNA flanking the transposon was done by Y linker and P6U primer (Table 1). DNA sequence flanking the transposon insertion site was identified by BLAST-N alignment with the recently

sequenced SE P125109 in the NCBI GenBank database (GenBank accession NO. AM933172.1).

#### Construction of the *rfbG* gene deletion mutant

The knock-out mutant, SE C50041 $\Delta$ *rfbG* was constructed by  $\lambda$ -Red recombination system [17]. Briefly, the *rfbG* gene was first substituted by a PCR adjusted antibiotic resistance cassette (Cm) using a  $\lambda$ -Red helper plasmid pKD46, which encode a series of phage recombinase. Recombinant clones were selected by plating on LB agar containing Cm. To resolve the antibiotic resistance cassettes (Cm), the temperature sensitive plasmid pCP20 was introduced. Finally, the *rfbG* gene was completely deleted from the start codon through the stop codon, as confirmed by sequencing. The slide agglutination tests were performed as above to determine whether SE C50041 $\Delta$ *rfbG* was rough strain.

#### Auto-aggregation assay LPS and SDS-PAGE silver staining of the mutants

The auto-aggregation assay was performed based on the method previously described by Zhou et al. [18]. Briefly, Salmonella cultures were statically grown in 5 ml LB medium at 37 °C for 16 h in test tubes. The upper 0.2 ml was carefully removed to measure its optical density (OD<sub>600</sub>) (recorded as OD<sub>600</sub> prevortex). The remaining culture in the test tube was then mixed by vortexing to re-suspend the aggregated cells, and 0.2 ml of the suspension was removed and its OD<sub>600</sub> was measured (recorded as OD<sub>600</sub> postvortex). The “percent aggregation” was calculated using the formula: 100% \* (OD<sub>600</sub> postvortex - OD<sub>600</sub> prevortex) / OD<sub>600</sub> postvortex.

Validation of the LPS phenotype occurred by SDS-PAGE and silver staining [19]. For this purpose LPS was isolated from SE C50041 and SE C50041 $\Delta$ *rfbG* using a commercially available LPS extraction kit (Intron biotechnology, Gyeonggi-do, Korea). The obtained LPS was separated by standard SDS-PAGE and was stained using a pierce<sup>®</sup> silver stain kit (Thermo, Rockford, USA).

#### Analysis of in vitro growth and biochemical characteristics of the mutants

For in vitro growth analysis of SE C50041, SE C50041 $\Delta$ *spiC*, SE C50041 $\Delta$ *spiC* - *rfbG*::Tn5Km2(Cm) and SE C50041 $\Delta$ *rfbG*. A single colony of each strain was subcultured in 5 ml LB broth and cultured at 37 °C with shaking at 180 rpm for at least 12 h. Subsequently the absorbance value of each strain was determined by spectrophotometry and cultures were diluted in 20 ml LB broth, then the absorbance value was determined by spectrophotometry to achieve an approx. initial concentration (OD<sub>600</sub> = 0.05) as a starting time point (0 h). The cultures were incubated at 37 °C with shaking at 100 rpm and the OD<sub>600</sub> was determined at time points of 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 h.

Each strain was tested in triplicate in two independent experiments. Biochemical traits of strains were tested by VITEK® 2 microbial identification system (bioMérieux, Marcy l'Etoile, France), including glucose, maltose, sucrose, mannose, mannitol, lactose, dulcitol, adonitol, sorbitol, malonate, lysine decarboxylase, ornithine decarboxylase, urea, H<sub>2</sub>S and so on.

#### Motility Assay

LB plates containing 0.3% (w/v) agar was used to characterize the motility phenotype of SE C50041, SE C50041 $\Delta$ *spiC*, SE C50041 $\Delta$ *spiC* - *rfbG*::Tn5Km2(Cm) and SE C50041 $\Delta$ *rfbG*. Overnight cultures of each strain were adjusted to the same optical density. Equal volume of suspensions were incubated on spots onto 0.3% LB agar. The plates were incubated at 37 °C for 5 h, and motility was assessed by examining the migration of the bacteria from the center of the inoculation point to the periphery of the plate [20]. The data were representative of three independent experiments, which gave similar results.

#### Preparation and identification of sera

The SPF chickens were obtained from Poultry Institute of Shandong Academy of Agricultural Science and the chickens were detected for free from any clinical signs of enteric disease and negative for *Salmonella*. All chickens were given formulated commercial feed and water throughout the experimental period. Experiments were undertaken in accordance with the permission of the Animal Care and Ethics Committee of Yangzhou University.

Three-week-old chickens were inoculated intramuscularly with 100  $\mu$ l of bacteria suspended in PBS solution and then a boost on day 14 after the first immunization, each bacteria inoculum was  $1 \times 10^8$  CFU (intramuscularly,  $n = 5$ ). Chickens were immunized respectively with SE C50041 $\Delta$ *spiC*, SE C50041 $\Delta$ *spiC* - *rfbG*::Tn5Km2(Cm) or SE C50041 $\Delta$ *rfbG*. A group of chickens was also infected with wild-type strain SE C50041. Five control chickens received 100  $\mu$ l of PBS via the same route. Sera from each animals (20  $\mu$ l) were mixed with some SE C50041 and observed for agglutination reaction [4].

The flocktype® *Salmonella* Ab ELISA kit (QIAGEN, Leipzig, Germany) was also used to determine the presence of serum antibody to the O-antigens 1, 4, 5, 9, and 12 as handbook indicated. An S/P ratio of  $\geq 0.3$  was considered positive while  $< 0.2$  was considered negative, samples with the S/P ratio  $\geq 0.2$  and  $< 0.3$  are doubtful.

#### Virulence assessment

BALB/c mice were obtained from the experimental animal centre of Yangzhou University. The mice were housed in an animal facility under a standard animal

study protocol. Experiments were undertaken in accordance with the permission of the Animal Care and Ethics Committee of Yangzhou University.

To investigate the virulence of SE C50041 $\Delta$ *rfbG* in BALB/c mice (6 - 8 weeks of age), Two groups of mice (each containing 25 mice) were infected with SE C50041 $\Delta$ *rfbG* and SE C50041. Mice in each group were further subdivided into five subgroups, each containing five mice. Each mouse in the C50041 $\Delta$ *rfbG* group was injected intraperitoneally with 10-fold dilutions of the strain from  $1 \times 10^8$  -  $1 \times 10^4$  CFU in 100  $\mu$ l PBS. Each mouse in the C50041 groups was injected intraperitoneally with 10-fold dilutions of the strain from  $1 \times 10^4$  -  $1 \times 10^0$  CFU in 100  $\mu$ l PBS. Five control mice received 100  $\mu$ l of PBS via the same route. Deaths were recorded up to day 14 and the LD<sub>50</sub> of each strain was calculated using the Karber and Behrens method [21].

#### Statistical analysis

All statistical analyses were performed using GraphPad Prism. *P* values  $< 0.05$  were considered significant when using one-way analysis of variance (ANOVA).

## Results

#### Identification of mutant *S. Enteritidis* showing smooth-to-rough phenotype

Out of 480 mutants screened, 1 potential mutant was not agglutinated with O<sub>9</sub> MAb or O<sub>9</sub> factor rabbit antiserum. To confirm that the transposon mutant had a rough phenotype, an acriflavine agglutination test was performed and the result showed that this strain was strongly agglutinated with acriflavine (Fig. 1a).


The sequence of the DNA flanking the transposon insertion site from this rough mutant was identified to be *rfbG* (region from 2176901 to 2177980 in SE P125109), which encodes a putative CDP-glucose 4,6-dehydratase.

#### Deleted mutant $\Delta$ *rfbG* of *S. Enteritidis* becoming rough pattern

The deletion mutant  $\Delta$ *rfbG* of *S. Enteritidis* was constructed by  $\lambda$ -Red recombination system. The slide agglutination tests showed that SE C50041 $\Delta$ *rfbG* was not agglutinated with O<sub>9</sub> MAb or O<sub>9</sub> factor rabbit antiserum, but was agglutinated with acriflavine (Fig. 1a). SE C50041 $\Delta$ *rfbG* also demonstrated smooth-to-rough transition.

#### Auto-aggregation of $\Delta$ *rfbG* mutants and SDS-PAGE silver staining of LPS

The auto-aggregation was tested in Luria-Bertani (LB) broth (Fig. 1b) and the "percent aggregation" was calculated using OD<sub>450</sub> measurements from these cultures. Both the SE C50041 and SE C50041 $\Delta$ *spiC* showed 5% aggregation, then the SE C50041 $\Delta$ *rfbG* and SE C50041 $\Delta$ *spiC*



-  $rfbG::Tn5Km2(Cm)$  demonstrated 48% and 69% aggregation, respectively (Fig. 1b).

LPS patterns obtained by standard Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of SE C50041, SE C50041 $\Delta spiC$ , SE C50041 $\Delta spiC$  -  $rfbG::Tn5Km2(Cm)$  and SE C50041 $\Delta rfbG$  are presented in Fig. 1a. It showed a visible loss of O-antigens and Core-LPS antigens for  $\Delta rfbG$  mutants (SE C50041 $\Delta rfbG$  and SE C50041 $\Delta spiC$  -  $rfbG::Tn5Km2(Cm)$ ) compared to SE C50041 or SE C50041 $\Delta spiC$ . There was no obvious difference between  $\Delta rfbG$  mutant and SE C50041 $\Delta spiC$  -  $rfbG::Tn5Km2(Cm)$  (Fig. 1c).

**Growth and biochemical characteristics of  $\Delta rfbG$  mutants**

Growth curve analysis revealed no significant differences between the wild-type and each mutant when cultured in LB broth at 37 °C (Fig. 2). Results of biochemical tests including glucose, maltose, sucrose, mannose, mannitol, lactose, dulcitol, adonitol, sorbitol, malonate, lysine decarboxylase, ornithine decarboxylase, urea, H<sub>2</sub>S and so on were the same between wild-type and each mutant, suggesting mutations in these genes do not alter the biochemical characteristics of *S. Enteritidis*.


**Motility of  $\Delta rfbG$  mutants**


Motility plates (Fig. 3) displayed a marked reduction in migration from the inoculation site to the periphery of the plate for SE C50041 $\Delta rfbG$  (2.5 mm) and SE C50041 $\Delta spiC$

(3.0 mm) when compared to SE C50041 (15.5 mm) and SE C50041 $\Delta spiC$  (14.5 mm). The data were representative of three independent experiments, which gave similar results.

**Sera tests**

Sera samples were collected at 14 days after the second immunization with SE C50041 $\Delta spiC$ , SE C50041 $\Delta spiC$  -  $rfbG::Tn5Km2(Cm)$ , SE C50041 $\Delta rfbG$ , SE C50041 or PBS control. Sera collected from SE C50041 $\Delta spiC$  -  $rfbG::Tn5Km2(Cm)$ , SE C50041 $\Delta rfbG$  and control groups were not agglutinated with SE C50041. In





**Fig. 3** Motility assay of  $\Delta rfbG$  mutants. Motility assay of the SE C50041, SE C50041 $\Delta spiC$ , SE C50041 $\Delta spiC - rfbG::Tn5Km2(Cm)$  and SE C50041 $\Delta rfbG$ . *S. Pullorum* S06004, was used as a negative control on swimming agar. After 5 h of incubation at 37 °C on swimming plates, the semi-diameter of each bacterial growth area was measured. These results shown are representative of three independent experiments. The migrations of strains are highlight using red arrows

contrast, sera collected from the other two groups showed obvious reaction (Table 2).

Sera samples of chicks immunized with  $\Delta rfbG$  mutants (SE C50041 $\Delta spiC - rfbG::Tn5Km2(Cm)$  ( $n = 5$ ) or SE C50041 $\Delta rfbG$  ( $n = 5$ )) and control animals ( $n = 5$ ) were considered *Salmonella* negative when using a commercially available flocktype® *Salmonella* Ab ELISA kit. Chicks immunized with SE C50041 $\Delta spiC$  ( $n = 5$ ) or SE C50041 ( $n = 5$ ) were considered seropositive for *Salmonella* in the ELISA test (Table 2). In conclusion,  $\Delta rfbG$  mutants without O-antigen do not stimulate animals to produce relevant antibody.

### Virulence of $\Delta rfbG$ mutant

To investigate the role of *rfbG* on the virulence, mice were injected intraperitoneally with SE C50041 $\Delta rfbG$  and SE C50041, and half-lethal dose ( $LD_{50}$ ) values were calculated according to the method of Karber and Behrens. The  $LD_{50}$  of  $\Delta rfbG$  was  $10^{6.69}$ , which was  $10^{6.6}$

-fold higher than that of SE C50041( $10^{0.13}$ ), implying that the virulence of the SE C50041 $\Delta rfbG$  was significantly decreased ( $P < 0.05$ ).

### Discussion

For gram-negative bacteria, including *Salmonella*, LPS are essential components of immunodominant antigens. For *Salmonella*, some LPS deficient mutants represent a promising research area. These mutants can not only result in attenuation, but also show structural (smooth-rough) transition that can be used as a marker for distinguishing isolates [19]. Therefore, the present study was performed to identify novel factors of *S. Enteritidis* that are important for smooth-to-rough transition.

STM is a powerful genetic tool that allows identification of genes that are important for different facets of pathogenesis and is well suited for screening rough strain in vitro. In this study, we first attempted to use O<sub>9</sub> MAb and O<sub>9</sub> factor rabbit antiserum to screen for signature-tagged transposon mutants of *S. Enteritidis* with slide agglutination tests. We found that *rfbG* gene was involved in smooth-to-rough transition in *S. Enteritidis*. Meanwhile, we also identified some other genes that involved in smooth-to-rough transition, e.g., *rfc* (data not shown), which has been used as a marker for distinguishing in *Salmonella enterica* vaccine research [22, 23]. In line with this, this new approach of using O<sub>9</sub> MAb and O<sub>9</sub> factor rabbit antiserum to screen *S. Enteritidis* signature-tagged transposon mutants to identify novel loci involved in smooth-to-rough transition is useful and reliable.

The *rfb* gene cluster of *S. Typhimurium* contains genes that are responsible for all or part of the biosynthetic pathways of dTDP-L-rhamnose, ODP-abequose and GDP-mannose, and are essential for O-antigen biosynthesis. Among them, the *rfbG* gene, which encodes a CDP-glucose 4,6-dehydratase, is a component of abequose biosynthetic pathway. CDP-glucose 4,6-dehydratase and glucose-1-phosphate cytidyltransferase (*rfbF*) are two enzymes required to promote the formation of CDP-4-keto-3,6-dideoxyglucose from CDP-4-keto-6-deoxyglucose (*rfbH* and *rfbI*), and abequose synthase (*rfbJ*) [24]. On the basis of amino-acid sequence homology, *S. Typhi* CDP-glucose 4,6-dehydratase is known to be a member of the short-chain dehydrogenase/reductase(SDR) superfamily, with the N-terminal domain contains a Rossmann fold and provides the platform for NAD(H) binding. The C-terminal domain is composed mostly of  $\alpha$ -helix and houses the binding pocket for the CDP portion of the CDP-xylose ligand. The xylose moiety extends into the active-site cleft that is located between the two domains [25]. It has also been demonstrated that the *rfbG*-negative *Azotobacter vinelandii* grown in liquid medium exhibited

**Table 2** Positive rate of sera tests (agglutination and ELISA)

Strains	Agglutination	ELISA
SE C50041	5/5	5/5
SE C50041 $\Delta spiC$	5/5	5/5
SE C50041 $\Delta rfbG$	0/5	0/5
SE C50041 $\Delta spiC - rfbG::Tn5Km2(Cm)$	0/5	0/5

agglutination, suggesting that *rfbG* gene is involved in surface structural transition [26].

It has been described that some LPS deficient mutants (*rfaJ*, *rfaL*, *rfaC*, et al.) were used in *Salmonella* DIVA-vaccine (Differentiation of Infected and Vaccinated Animals) research [19, 27, 28]. In the present study, the virulence change of the *rfbG* mutant strain were measured in mouse model. The result demonstrated that *rfbG* mutant strain is safe to mammal. Furthermore, SE Slide Agglutination test and ELISA test showed that *rfbG* mutants do not stimulate animals to produce agglutinating antibody, which may help to distinguish animals vaccinated with this mutant from those infected by field strains. Overall, *rfbG* mutant showed a potential “DIVA” capacity. Nevertheless, as a candidate vaccine, *rfbG* mutant needs further study.

In addition, results obtained from motility assays indicate that the deletion of *rfbG* gene resulted in variation in swimming motility, suggesting that flagellar assembly and function may be influenced by the altered LPS structures. Deditius et al. described that a *rfaG* mutant diminished flagellar assembly and significantly reduced transcription of flagellar class II and class III promoters, but not of the class I promoter. Moreover, FlhC protein levels were reduced in the *rfaG* mutant strain. They concluded that a defect in LPS biosynthesis regulates motility by affecting FlhDC stability or translation of its mRNA on a posttranscriptional level via an unknown mechanism [29]. Moreover, the results obtained from SDS-PAGE silver staining of LPS show that  $\Delta rfbG$  mutants not only lead to loss of O-antigens but also lead to loss of Core-LPS antigens. It suggested that deficiency in *rfbG* leads to deep loss of LPS synthesis. The mechanism of *rfbG* affect LPS biosynthesis need further studies.

## Conclusions

We used O<sub>9</sub> MAb and O<sub>9</sub> factor rabbit antiserum to screen *S. Enteritidis* signature-tagged transposon mutants to identify novel factors involved in smooth-to-rough transition. The present study demonstrated that *rfbG* gene inserted/deletion mutant of *S. Enteritidis* showed almost the same biological characteristics, attenuation, distinguishable reaction (agglutination and ELISA) and other rough strain characteristics. Thus, this approach may be used more broadly in exploring LPS biosynthesis, and as a high-throughput tool for screening rough strains which were used as markers in developing DIVA-vaccine.

## Abbreviations

Amp: Ampicillin; ANOVA: One-way analysis of variance; CI: Competitive index; Cm: Chloromycetin; DAP: 2,6-diaminopimelic acid; Km: Kanamycin; LB: Luria-Bertani; LD<sub>50</sub>: Half-lethal dose; LPS: Lipopolysaccharide; O<sub>9</sub> MAb: Monoclonal antibody against somatic O<sub>9</sub> antigen; PBS: Phosphate-buffered saline; *S. Enteritidis*

SE: *Salmonella enterica* serovar Enteritidis; SDS-PAGE: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis; STM: Signature-tagged mutagenesis

## Acknowledgements

The authors would like to thank Mr Yachen Hu, Ms Xiaochun Wang, Ms. Huijuan Zheng and Mr Zemiao Xia for technical support and Ms Xianyue Zhai and Ms Jiqin Xu for animal husbandry support.

## Funding

This work was supported by the National Key Research and Development Program Special Project (2016YFD0501607), the Special Fund for Agroscientific Research in the Public Interest (201403054), the National Natural Science Foundation of China (nos. 31320103907 and 31230070), the Graduate Research and Innovation Projects in Jiangsu Province (KYZZ15\_0366), the “Six Talent Peaks Program” of Jiangsu Province (NY-028), the Yangzhou University Science and Technology Innovation Team, and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

## Availability of data and materials

The information supporting the conclusions of this article is included within the article.

## Authors' contributions

ZMP, XFL, SZG and YJ designed of the study; YJ and XLK performed the construction and screening of transposon mutant library screening; YJ, RXG and JLY performed the the tests for molecular and phenotypic characteristics of mutant strains; YJ, RXG, PPT and KYW performed the animal experiment; SZG, QCL, JS and XHZ analyzed the data; JYG contributed reagents/materials; ZMP, XFL, SZG, JYG, XLK and XAJ supervised the study; YJ, ZMP, XFL and XHZ wrote the paper. All authors read and approved the final manuscript.

## Competing interests

The authors declare that they have no competing interests.

## Consent for publication

Not applicable.

## Ethics approval

Experiments were undertaken in accordance with the permission of the Animal Care and Ethics Committee of Yangzhou University.

## Author details

<sup>1</sup>Jiangsu Key Laboratory of Zoonosis, Yangzhou University, 48 East Wenhui Road, Yangzhou, Jiangsu 225009, China. <sup>2</sup>Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, Jiangsu 225009, China. <sup>3</sup>Division of Gastroenterology and Hepatology Department of Medicine, University of Illinois at Chicago, 840 S Wood Street, Room 704 CSB, 60612 Chicago, IL, USA. <sup>4</sup>Pathobiology and Veterinary Science, College of Agriculture, Health and Natural Resources, University of Connecticut, 61 North Eagleville Road, Unit-3089, Mansfield, CT, USA.

Received: 10 September 2016 Accepted: 8 February 2017

Published online: 03 March 2017

## References

- Patrick ME, Adcock PM, Gomez TM, Altekuse SF, Holland BH, Tauxe RV, Swerdlow DL. *Salmonella enteritidis* infections, United States, 1985-1999. *Emerg Infect Dis*. 2004;10(1):1-7.
- Keller LH, Benson CE, Krotec K, Eckroade RJ. *Salmonella* Enteritidis colonization of the reproductive tract and forming and freshly laid eggs of chickens. *Infect Immun*. 1995;63(7):2443-9.
- Jawale CV, Lee JH. Characterization of adaptive immune responses induced by a new genetically inactivated *Salmonella* Enteritidis vaccine. *Comp Immunol Microbiol Infect Dis*. 2014;37(3):159-67.
- Lalsiamthara J, Gogia N, Goswami TK, Singh RK, Chaudhuri P. Intermediate rough *Brucella abortus* S19Δper mutant is DIVA enable, safe to pregnant guinea pigs and confers protection to mice. *Vaccine*. 2015;33(22):2577-83.
- Schnaitman CA, Klens JD. Genetics of lipopolysaccharide biosynthesis in enteric bacteria. *Microbiol Rev*. 1993;57(3):655-82.

6. Matiasovic J, Stepanova H, Volf J, Kubala L, Ovesna P, Rychlik I, Faldyna M. Influence of the lipopolysaccharide structure of *Salmonella enterica* serovar Enteritidis on interactions with pig neutrophils. *Vet Microbiol.* 2011;150(1-2):167–72.
7. Bearson BL, Bearson SM, Kich JD. A DIVA vaccine for cross-protection against *Salmonella*. *Vaccine.* 2016;34(10):1241–6.
8. Roman BS, Garrido V, Munoz PM, Arribillaga L, Garcia B, De Andres X, Zabaleta V, Mansilla C, Farran I, Lasa I, De Andres D, Amorena B, Lasarte JJ, Grillo MJ. The extradomain a of fibronectin enhances the efficacy of lipopolysaccharide defective *Salmonella* bacterins as vaccines in mice. *Vet Res.* 2012;43:31.
9. Ku YW, McDonough SP, Palaniappan RU, Chang CF, Chang YF. Novel attenuated *Salmonella enterica* serovar Choleraesuis strains as live vaccine candidates generated by signature-tagged mutagenesis. *Infect Immun.* 2005;73(12):8194–203.
10. Shah DH, Zhou XH, Kim HY, Call DR, Guard J. Transposon mutagenesis of *Salmonella enterica* serovar Enteritidis identifies genes that contribute to invasiveness in human and chicken cells and survival in egg albumen. *Infect Immun.* 2012;80(12):4203–15.
11. Geng S, Jiao X, Barrow P, Pan Z, Chen X. Virulence determinants of *Salmonella* Gallinarum biovar Pullorum identified by PCR signature-tagged mutagenesis and the *spiC* mutant as a candidate live attenuated vaccine. *Vet Microbiol.* 2014;168(2-4):388–94.
12. Mikael R, Duncan M, Pietro M, John T. *Salmonella*: Molecular Biology and Pathogenesis. Wymondham: Horizon Bioscience; 2007.
13. World Organisation for Animal Health. Manual of diagnostic tests and vaccines for terrestrial animals. Chapter 2.9.8: *Salmonellosis*. 2016. <http://www.oie.int/en/international-standard-setting/terrestrial-manual/access-online/>.
14. Jiao X, Zhang R, Gan J, Liu X. Production and characterization of monoclonal antibodies specific for O-antigens of *Salmonella* serogroups A-F. *Chin J Zoonoses.* 1989;5:11–4 (in Chinese).
15. Hu M, Yang Y, Meng C, Pan Z, Jiao X. Responses of macrophages against *Salmonella* infection compared with phagocytosis. *In Vitro Cell Dev Biol Anim.* 2013;49(10):778–84.
16. Zeng L, Li B, Yan S, Pan Z, Geng S, Jiao X. Construction of genetically engineered attenuated vaccines *Salmonella enteritidis* C50041 $\Delta$ *spiC* $\Delta$ *crp*. *Chin J Zoonoses.* 2015;31(2):97–101 (in Chinese).
17. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci U S A.* 2000;97(12):6640–5.
18. Zhou X, Liu B, Shi C, Shi X. Mutation of a *Salmonella* serogroup-C1-specific gene abrogates O<sub>7</sub>-antigen biosynthesis and triggers NaCl-dependent motility deficiency. *PLoS One.* 2014;9(9), e106708.
19. Leyman B, Boyen F, Van Parys A, Verbrugge E, Haesebrouck F, Pasmans F. *Salmonella* Typhimurium LPS mutations for use in vaccines allowing differentiation of infected and vaccinated pigs. *Vaccine.* 2011;29(20):3679–85.
20. Yim L, Betancor L, Martinez A, Giossa G, Bryant C, Maskell D, Chabalgoity JA. Differential phenotypic diversity among epidemic-spanning *Salmonella enterica* serovar enteritidis isolates from humans or animals. *Appl Environ Microbiol.* 2010;76(20):6812–20.
21. Gilles HJ. Calculation of the index of acute toxicity by the method of linear regression. Comparison with the method of "Karber and Behrens". *Eur J Toxicol Environ Hyg.* 1974;7(2):77–84.
22. Collins LV, Attridge S, Hackett J. Mutations at *rfc* or *pmi* attenuate *Salmonella typhimurium* virulence for mice. *Infect Immun.* 1991;59(3):1079–85.
23. Kong Q, Liu Q, Jansen AM, Curtiss R. Regulated delayed expression of *rfc* enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated *Salmonella enterica* vaccines. *Vaccine.* 2010;28(37):6094–103.
24. Jiang XM, Neal B, Santiago F, Lee SJ, Romana LK, Reeves PR. Structure and sequence of the *rfb* (O antigen) gene cluster of *Salmonella* serovar typhimurium (strain LT2). *Mol Microbiol.* 1991;5(3):695–713.
25. Koropatkin NM, Holden HM. Structure of CDP-D-glucose 4,6-dehydratase from *Salmonella typhi* complexed with CDP-D-xylose. *Acta Crystallogr D Biol Crystallogr.* 2005;61(Pt 4):365–73.
26. Gavini N, Hausman BS, Pulakat L, Schreiner RP, Williamson JA. Identification and mutational analysis of *rfbG*, the gene encoding CDP-D-glucose-4,6-dehydratase, isolated from free living soil bacterium *Azotobacter vinelandii*. *Biochem Biophys Commun.* 1997;240(1):153–61.
27. Kong Q, Yang J, Liu Q, Alamuri P, Roland KL, Curtiss R. Effect of deletion of genes involved in lipopolysaccharide core and O-antigen synthesis on virulence and immunogenicity of *Salmonella enterica* serovar typhimurium. *Infect Immun.* 2011;79(10):4227–39.
28. Kwon HJ, Cho SH. Pathogenicity of SG 9R, a rough vaccine strain against fowl typhoid. *Vaccine.* 2011;29(6):1311–8.
29. Deditius JA, Felgner S, Spöring I, Kühne C, Frahm M, Rohde M, Weiß S, Erhardt M. Characterization of Novel Factors Involved in Swimming and Swarming Motility in *Salmonella enterica* Serovar Typhimurium. *PLoS One.* 2015;10(8), e0135351.
30. Geng SZ, Jiao XA, Pan ZM, Chen XJ, Zhang XM, Chen X. An improved method to knock out the *asd* Gene of *Salmonella enterica* serovar Pullorum. *J Biomed Biotechnol.* 2009;2009:646380.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

